Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
gusacitinib × Clear all
NCT06238531 2025-03-13

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Lymphoid

Lupus Erythematosus, Systemic, Lymphoma, Follicular

NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02550678 2018-06-06

ASN-002-001

Ascend Biopharmaceuticals Ltd

Phase 1/2 Completed
16 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡